crews craig (6 Ergebnisse)

Hardcover. Zustand: Good. Zustand des Schutzumschlags: No Dust Jacket. Crews, Monte (illustrator). 2nd printing. Moderate wear to the purple covers; pages are discolored with age; name inside; a good solid book. Illustrator: Crews, Monte. Quantity Available: 1. Category: Fiction; Inventory No: 155791.

Hardcover. Zustand: Good. Zustand des Schutzumschlags: No Dust Jacket. Crews, Monte (illustrator). Signed by Author. Moderate wear to the purple covers; some soiling to the bottom of the spine and cover; pages toned; a good book. Inscribed and signed by the author inside. Illustrator: Crews, Monte. Quantity Available: 1. Category: Fiction; Signed by Author. Inventory No: 160301.

Gebunden. Zustand: New. This book provides a comprehensive overview from the leading academic and industrial experts on recent developments, scope and limitations in this dynamically growing research area an ideal reference work for researchers in drug discovery and chemical biol.

Zustand: New. In.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Buch. Zustand: Neu. Neuware - Targeting protein degradation using small molecules is one of the most exciting therapeutic strategies in decades and a rapidly growing area of research. Since a large portion of the proteome lacks a small molecule ligand or enzymatic active site, there has been much interest in the development of novel technologies to address this so far undruggable proteome. In particular, the development of proteolysis targeting chimera (PROTACs) as potential drugs capable of recruiting target proteins to the cellular quality control machinery for elimination has opened new avenues for chemical biology and drug discovery to address traditionally 'difficult to target' proteins. Since their initial description, PROTACs have been shown to be a versatile technology capable of inducing the degradation of a great variety of proteins including transcription factors, kinases, cytosolic proteins, and nuclear epigenetic readers. The broad applicability of this approach with regard to the different types of intracellular proteins that can be degraded and the variety of E3 ligases that can be engaged suggests that future PROTAC-based drugs could be developed to treat a broad spectrum of severe diseases. Leading academic and industrial experts deliver an overview of recent trends in controlling protein levels within cells by applying small molecule tools and drugs including an outlook on current and future developments of protein degrading small molecules and beyond.